Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1973 Oct 1;138(4):754–763. doi: 10.1084/jem.138.4.754

STUDIES IN PORPHYRIA

II. EVIDENCE FOR A DEFICIENCY OF STEROID Δ4-5α-REDUCTASE ACTIVITY IN ACUTE INTERMITTENT PORPHYRIA

H Leon Bradlow 1, Peter N Gillette 1, T F Gallagher 1, Attallah Kappas 1
PMCID: PMC2180579  PMID: 4270345

Abstract

Patients with the genetic liver disease, acute intermittent porphyria (AIP), have a defect in the reductive transformation of steroid hormones that is manifest by the disproportionate generation of 5β-steroid metabolites from precursor hormones. 5β-steroid metabolites were earlier shown to be potent inducers experimentally of δ-aminolevulinate synthetase (ALAS), the mitochondrial enzyme that is rate-limiting in porphyrin synthesis, and that is found at high levels of activity in the livers of AIP patients. In this report, the basis for the defective steroid metabolism in AIP has been shown, through studies with the 14C-labeled adrenal hormone 11β-hydroxy-Δ4-androstenedione, to reside in a substantial deficiency of hepatic steroid Δ4-5α-reductase activity. This enzymic deficiency was found in all seven AIP patients studied, and ranged from 34% to as much as 70% below the mean enzyme activity characterizing normal subjects. The functional consequence of the low levels of 5α-reductase activity in AIP is to divert the reductive transformation of certain natural hormones from the 5α- to the 5β-pathway; the latter is the metabolic route through which endogenous steroids having the potential for inducing hepatic ALAS are generated. It is not presently known whether the 5α-reductase deficiency in AIP is acquired in some fashion or whether it has partial genetic determinants. It seems probable, however, that this enzymatic abnormality, coupled with the dramatic increase in hormone synthesis that occurs at puberty, may be of major importance in determining clinical expression of the latent gene defect for AIP in many individuals. The 5α-reductases for steroid hormones are known to be localized in the endoplasmic reticulum of hepatic cells and the present findings in AIP thus represent the first demonstration that an enzymic component of these membranous structures is functionally abnormal in this hereditary liver disease.

Full Text

The Full Text of this article is available as a PDF (522.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRADLOW H. L., GALLAGHER T. F. Metabolism of 11 beta-hydroxy-delta 4-androstene-3,17-dione in man. J Biol Chem. 1957 Nov;229(1):505–518. [PubMed] [Google Scholar]
  2. Bradlow H. L., Zumoff B., Fukushima D. K., Hellman L., Bickers D. R., Alvares V. P., Kappas A. Drug-induced alterations of steroid hormone metabolism in man. Ann N Y Acad Sci. 1973;212:148–155. doi: 10.1111/j.1749-6632.1973.tb47593.x. [DOI] [PubMed] [Google Scholar]
  3. Bradlow H. L., Zumoff B., Fukushima D. K., Hellman L., Gallagher T. F. Metabolism of 11 beta-hydroxy-delta 4-androstene-3,17-dione: effect of thyroid hormone. J Clin Endocrinol Metab. 1966 Sep;26(9):949–954. doi: 10.1210/jcem-26-9-949. [DOI] [PubMed] [Google Scholar]
  4. DOBRINER K. Studies in steroid metabolism. XIX. The alpha-ketosteroid excretion pattern in normal males. J Clin Invest. 1953 Oct;32(10):940–949. doi: 10.1172/JCI102819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. GALLAGHER T. F., KAPPAS A., LASZLO D., SPENCER H. Influence of invasiveness, hormones, and amphenone on steroids in adrenal carcinoma. Science. 1956 Sep 14;124(3220):487–489. doi: 10.1126/science.124.3220.487-a. [DOI] [PubMed] [Google Scholar]
  6. GRANICK S., URATA G. Increase in activity of alpha-aminolevulinic acid synthetase in liver mitochondria induced by feeding of 3,5-dicarbethoxy-1,4-dihydrocollidine. J Biol Chem. 1963 Feb;238:821–827. [PubMed] [Google Scholar]
  7. Granick S., Kappas A. Steroid induction of porphyrin synthesis in liver cell culture. I. Structural basis and possible physiological role in the control of heme formation. J Biol Chem. 1967 Oct 25;242(20):4587–4593. [PubMed] [Google Scholar]
  8. Granick S., Sassa S., Granick J. L., Levere R. D., Kappas A. Assays for porphyrins, delta-aminolevulinic-acid dehydratase, and porphyrinogen synthetase in microliter samples of whole blood: applications to metabolic defects involving the heme pathway. Proc Natl Acad Sci U S A. 1972 Sep;69(9):2381–2385. doi: 10.1073/pnas.69.9.2381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. HELLMAN L., BRADLOW H. L., ZUMOFF B., FUKUSHIMA D. K., GALLAGHER T. F. Thyroid-androgen interrelations and the hypocholesteremic effect of androsterone. J Clin Endocrinol Metab. 1959 Aug;19:936–948. doi: 10.1210/jcem-19-8-936. [DOI] [PubMed] [Google Scholar]
  10. KAPPAS A., DOBRINER K., GALLAGHER T. F. Studies in steroid metabolism. XXVII. A comparison of the steroid response to ACTH and cortisone in normal young men. J Clin Invest. 1955 Oct;34(10):1559–1565. doi: 10.1172/JCI103208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. KAPPAS A., GALLAGHER T. F. Study of the genetic and extragenetic determinants of alpha-ketosteroid production in man. J Clin Invest. 1960 Apr;39:620–625. doi: 10.1172/JCI104076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kappas A., Bradlow H. L., Gillette P. N., Gallagher T. F. Abnormal steroid hormone metabolism in the genetic liver disease acute intermittent porphyria. Ann N Y Acad Sci. 1971 Jul 6;179:611–624. doi: 10.1111/j.1749-6632.1971.tb46937.x. [DOI] [PubMed] [Google Scholar]
  13. Kappas A., Bradlow H. L., Gillette P. N., Gallagher T. F. Studies in porphyria. I. A defect in the reductive transformation of natural steroid hormones in the hereditary liver disease, acute intermittent porphyria. J Exp Med. 1972 Nov 1;136(5):1043–1053. doi: 10.1084/jem.136.5.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kappas A., Granick S. Steroid induction of porphyrin synthesis in liver cell culture. II. The effects of heme, uridine diphosphate glucuronic acid, and inhibitors of nucleic acid and protein synthesis on the induction process. J Biol Chem. 1968 Jan 25;243(2):346–351. [PubMed] [Google Scholar]
  15. Levere R. D., Kappas A. Biochemical and clinical aspects of the porphyrias. Adv Clin Chem. 1968;11:133–174. doi: 10.1016/s0065-2423(08)60058-x. [DOI] [PubMed] [Google Scholar]
  16. Meyer U. A., Strand L. J., Doss M., Rees A. C., Marver H. S. Intermittent acute porphyria--demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med. 1972 Jun 15;286(24):1277–1282. doi: 10.1056/NEJM197206152862401. [DOI] [PubMed] [Google Scholar]
  17. Paulsen E. P., Sobel E. H., Shafran M. S. Urinary steroid metabolites in children. I. Individual 17-ketosteroids in children with normal sexual development. J Clin Endocrinol Metab. 1966 Mar;26(3):329–339. doi: 10.1210/jcem-26-3-329. [DOI] [PubMed] [Google Scholar]
  18. TSCHUDY D. P., PERLROTH M. G., MARVER H. S., COLLINS A., HUNTER G., Jr, RECHCIGL M., Jr ACUTE INTERMITTENT PORPHYRIA: THE FIRST "OVERPRODUCTION DISEASE" LOCALIZED TO A SPECIFIC ENZYME. Proc Natl Acad Sci U S A. 1965 Apr;53:841–847. doi: 10.1073/pnas.53.4.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. VESTERGAARD P. URINARY EXCRETION OF INDIVIDUAL 17-KETOSTEROIDS IN CHILDREN. Acta Endocrinol (Copenh) 1965 Jul;49:436–442. doi: 10.1530/acta.0.0490436. [DOI] [PubMed] [Google Scholar]
  20. WATSON C. J. Porphyria. Adv Intern Med. 1954;6:235–299. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES